Advertisement
Screener

Vaxart, Inc. (VXRT) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

Vaxart, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate

Vaxart, Inc. (VXRT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate of 0.67% for the 12-month period ending 2017-06-30, per its 10-K filed 2017-09-01.

Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate · last filed 2017-09-01

  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2017-03-31 was 0.65%, a 14.47% decline year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2016-09-30 was 0.76%, a 1.33% increase year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2016-03-31 was 0.76%, a 2.56% decline year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for the quarter ending 2015-09-30 was 0.75%, a 8.54% decline year-over-year.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2017 was 0.67%, a 10.67% decline from fiscal 2016.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2016 was 0.75%, a 8.54% decline from fiscal 2015.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2015 was 0.82%, a 3.80% increase from fiscal 2014.
  • Vaxart, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, weighted average volatility rate for fiscal 2014 was 0.79%, a 0.00% change from fiscal 2013.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate 12 month
2017-06-300.67%
10-K · filed 2017-09-01
2017-03-310.65%
10-Q · filed 2017-05-08
0.71%
10-Q · filed 2017-05-08
2016-09-300.76%
10-Q · filed 2016-11-08
2016-06-300.75%
10-K · filed 2017-09-01
2016-03-310.76%
10-Q · filed 2017-05-08
0.75%
10-Q · filed 2017-05-08
2015-09-300.75%
10-Q · filed 2016-11-08
2015-06-300.82%
10-K · filed 2016-09-13
2015-03-310.78%
10-Q · filed 2015-05-08
0.82%
10-Q · filed 2015-05-08
2014-12-310.82%
10-Q · filed 2015-02-06
0.82%
10-Q · filed 2015-02-06
2014-09-300.82%
10-Q · filed 2015-11-06
2014-06-300.79%
10-K · filed 2016-09-13
2014-03-310.78%
10-Q · filed 2015-05-08
0.78%
10-Q · filed 2015-05-08
2013-12-310.78%
10-Q · filed 2015-02-06
0.78%
10-Q · filed 2015-02-06
2013-06-300.79%
10-K · filed 2015-09-11
2013-03-310.84%
10-Q · filed 2014-05-12
2012-12-310.84%
10-Q · filed 2014-02-10
0.84%
10-Q · filed 2014-02-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48
Pelthos Therapeutics Inc. (PTHS)United States$0.086B-1.20
CHAMPIONS ONCOLOGY, INC. (CSBR)United States$0.070B-68.02
COGNITION THERAPEUTICS INC (CGTX)United States$0.090B-6.52
BioStem Technologies, Inc. (BSEM)United States$0.069B
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Cardiff Oncology, Inc. (CRDF)United States$0.101B-2.22
EXOZYMES INC. (EXOZ)United States$0.058B